Evidence map›Paper›PMID 42465855›Full record

ReviewOncology letters2026

Regulatory roles of N6-methyladenosine methylation factors in melanoma invasion and metastasis (Review).

Zhijie Xu, Wanqun Yu, Jie Liu, Xiyue Chang, Shiraz Manji Laeeqa, Zerong Xu, Qi Yang, Wanan Xiao

Abstract readReview
In one paragraph

Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhijie XuDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Wanqun YuOperating Room, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Jie LiuDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Xiyue ChangDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Shiraz Manji LaeeqaDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Zerong XuDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Qi YangDepartment of Orthopedics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Wanan XiaoDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma, a malignant skin tumor, has an increasing incidence rate annually and affects the skin, eyes and mucous membranes. Despite advancements in early diagnosis and treatment improving survival rates, invasion and metastasis of melanoma remain major challenges. In-depth research into the pathogenesis of melanoma and novel therapies is essential to enhance patient outcomes. N6-methyladenosine (m6A) methylation, a key RNA modification, regulates gene expression and cellular functions, influencing cell proliferation, differentiation, apoptosis and signal transduction. It is implicated in various diseases, including tumors. In melanoma, m6A methylation regulates genes involved in tumor invasion and metastasis, impacting cell migration and drug resistance. Understanding the role of m6A methylation in melanoma can uncover disease mechanisms and inform therapeutic strategies.

Indexed as

invasionmelanomametastasisN6-methyladenosine methylation

Identifiers

PMID42465855
PMCPMC13373681

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.